Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty

BACKGROUND: Impaired endogenous stem cell repair capacity is hypothesized to be a biologic basis of frailty. Therapies that restore regenerative capacity may therefore be beneficial. This Phase 1 study evaluated the safety and potential efficacy of intravenous, allogeneic, human mesenchymal stem cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Golpanian, Samuel, DiFede, Darcy L, Khan, Aisha, Schulman, Ivonne Hernandez, Landin, Ana Marie, Tompkins, Bryon A, Heldman, Alan W, Miki, Roberto, Goldstein, Bradley J, Mushtaq, Muzammil, Levis-Dusseau, Silvina, Byrnes, John J, Lowery, Maureen, Natsumeda, Makoto, Delgado, Cindy, Saltzman, Russell, Vidro-Casiano, Mayra, Pujol, Marietsy V, Da Fonseca, Moisaniel, Oliva, Anthony A, Green, Geoff, Premer, Courtney, Medina, Audrey, Valasaki, Krystalenia, Florea, Victoria, Anderson, Erica, El-Khorazaty, Jill, Mendizabal, Adam, Goldschmidt-Clermont, Pascal J, Hare, Joshua M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
The Journal of Gerontology: Translational Articles: Stem Cell Transplantation for Frailty
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861970/
https://www.ncbi.nlm.nih.gov/pubmed/28444181
http://dx.doi.org/10.1093/gerona/glx056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861970/
https://www.ncbi.nlm.nih.gov/pubmed/28444181
http://dx.doi.org/10.1093/gerona/glx056

Ejemplares similares